Vertex Pharma (VRTX) Misses Q4 EPS by 5c; offers guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $528.04 +6.03%
Revenue Growth %: +8.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
CRMT, More
Revenue Growth %: +8.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $5.03, $0.05 worse than the analyst estimate of $5.08. Revenue for the quarter came in at $3.19 billion versus the consensus estimate of $3.18 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $12.95-13.1 billion, versus the consensus of $13.001 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
- Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
